research
A $100,000 Grant Backs Pediatric AML CAR-T Work
Roswell Park received an Impact Award to advance a proposed therapy for children with relapsed or treatment-resistant acute myeloid leukemia.
Summary
Roswell Park received an Impact Award to advance a proposed therapy for children with relapsed or treatment-resistant acute myeloid leukemia.
The award supports David Byrwa?s research program and brings the donor?s cumulative Roswell Park giving to $1 million. It funds development toward evaluation; it is not evidence that the therapy is safe or effective.
Why it matters
Roswell Park received an Impact Award to advance a proposed therapy for children with relapsed or treatment-resistant acute myeloid leukemia.
Limits and context
- It funds development toward evaluation; it is not evidence that the therapy is safe or effective.
Key claims
Roswell Park received an Impact Award to advance a proposed therapy for children with relapsed or treatment-resistant acute myeloid leukemia.
Qualification: It funds development toward evaluation; it is not evidence that the therapy is safe or effective.
Evidence: source-2026-07-24-020
Sources
- Roswell Park via Newswise: Pediatric AML CAR-T grantRoswell Park via Newswise · secondary reporting
Corrections
No corrections have been recorded for this story.